Nutritional Shakes Causing Listeria Infection Have Been Recalled From The Shelves

Updated Feb 25, 2025 | 03:00 PM IST

SummaryListeria found in shakes have caused a massive recall, as the infection had been linked to many people getting sick, hospitalized as well as deaths. Here is what you need to know about this disease and who it affects the most.
(Credit-Canva)

(Credit-Canva)

FDA has recalled a range of milkshakes from sales as the link between the deaths and serious illnesses caused by it were confirmed. The 4 oz. packs of Lyons ReadyCare and Sysco Imperial Frozen Supplemental Shakes were taken off shelf as the dangerous consequences of consuming the drink were found, there are 11 confirmed deaths, 27 hospitalized and 34 people who have been infected as well with Listeria. This massive recall was a voluntary effort, FDA did not explain when this death took place but specified that the outbreak could be traced back seven years.

According to the Cleveland clinic, Listeria is a foodborne illness which is caused by L. monocytogenes. Lyons Magnus, the company that provides these shakes to many places, is taking the lead. They are pulling back all of their 4-ounce packs of two specific milkshake brands. This comes after their supplier, Prairie Farms, found the problem at their factory. It's like finding a bad apple in a big bag and then taking the whole bag away to be safe. The goal is to stop anyone else from drinking these contaminated shakes.

How Has This Impacted The Vulnerable Populations?

This outbreak is especially concerning because it has hit people who are already weak or sick. Many of those who got ill were living in places like nursing homes or were in hospitals. These places often serve these kinds of supplemental shakes to people who need extra nutrition. Sadly, many of the people who got sick were already dealing with other health problems, which made the Listeria infection even more dangerous. Records show that these milkshakes were being given to patients and residents, meaning they were readily available. The fact that so many vulnerable people were affected highlights the importance of very strict food safety, especially in places that care for those with health issues. The FDA was first alerted about this problem late last year, showing that this has been an ongoing issue.

Finding out where a food poisoning outbreak started is like being a detective. Companies like Lyons Magnus acted quickly when they learned about the Listeria. They stopped getting any more shakes from the factory where the problem was found. They also told all of their customers to get rid of any of the bad shakes. But health officials are also looking further back. They have found that this outbreak can be traced back to 2018. This means that the bacteria might have been in the food system for a long time. Investigators are now working to find out exactly how and where the food was contaminated all those years ago. This kind of investigation is important to prevent future outbreaks.

What Are The Risks And Symptoms Of Listeria?

Listeria is a type of bacteria that can make people very sick. If you eat food that has Listeria in it, you might not feel sick right away. It can take up to 10 weeks for symptoms to show up, but usually, it's about two weeks. The symptoms can include things like a fever, muscle aches, and feeling sick to your stomach. In serious cases, people can get confused, have a stiff neck, or even have seizures. Some people are more likely to get very sick from Listeria. These include pregnant women, older adults, and people whose immune systems are weak. Because of this, it is very important that these at risk groups of people avoid the recalled products. Also, this information reminds us that Listeria is a dangerous bacteria, that has caused other outbreaks from other food products.

End of Article

FDA Escalates Recall Of 64,800 Lbs. of Butter Over Undeclared Allergen

Updated Aug 3, 2025 | 07:23 AM IST

SummaryThe FDA has escalated a nationwide butter recall by Bunge North America to Class II due to undeclared milk. Over 64,000 pounds were recalled, posing allergy risks to sensitive individuals despite no reported illnesses.
FDA Escalates Recall Of 64,800 Lbs. of Butter Over Undeclared Allergen

Credits: Canva

In a growing food safety alert, the U.S. Food and Drug Administration (FDA) has escalated a butter recall to a Class II risk level following concerns over undeclared allergens. The product in question, European Style Butter Blend manufactured by Bunge North America Inc., was found to contain milk that was not listed on the packaging label.

Class II Recall Indicates Moderate Health Risk

The risk reclassification, issued on Wednesday, July 30, places the product under the FDA’s second-highest warning level. According to the FDA, a Class II recall involves “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

While no illnesses or allergic reactions have been reported so far, the undeclared presence of milk poses a potential health hazard to people with dairy allergies or lactose intolerance.

Initial Voluntary Recall Announced in Mid-July

The recall began as a voluntary measure by Bunge on July 14, when the company announced it was pulling approximately 64,800 pounds, or 1,800 cases, of its one-pound butter blocks from shelves. The recalled butter was packed in white paperboard cases, each containing 36 one-pound blocks.

The affected products carry the lot code 5064036503 and were shipped to 12 distribution centers across the United States and one in the Dominican Republic.

Why the Undeclared Milk Is a Serious Concern

Milk is one of the nine major food allergens identified by the FDA, alongside eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The FDA mandates clear labeling of such allergens because exposure, even in small amounts, can cause a range of reactions, from mild discomfort to life-threatening symptoms.

Food-related allergic reactions may include hives, facial swelling, vomiting, coughing, and skin irritation. More severe responses can result in anaphylaxis, a rapid-onset, whole-body allergic reaction that may lead to shock and, in extreme cases, death.

According to the Mayo Clinic, anaphylaxis occurs when the immune system floods the body with chemicals in response to an allergen. This can cause a sudden drop in blood pressure, narrowing of the airways, and potential organ failure if not treated immediately.

FDA Reiterates Importance of Allergen Labeling

In light of the recall, the FDA has emphasized the importance of allergen labeling and said it continues to enforce regulations requiring companies to clearly list all ingredients and potential allergens on packaging.

“More specific labeling requirements exist for foods that can cause allergies or other hypersensitivity reactions,” the agency stated. “These rules are designed to prevent accidental consumption of allergens and to protect consumers with dietary restrictions.”

The FDA also advised that anyone who experiences symptoms of an allergic reaction after consuming the recalled butter should “stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine), and seek medical attention.”

Company Yet to Comment

As of August 2, Bunge North America has not issued an updated public statement in response to the FDA’s reclassification and did not respond to a request for comment.

Food Safety Under Scrutiny Amid Other Recent Recalls

This butter recall follows a string of other high-profile food safety incidents this year. In recent weeks, more than 110,000 cases of popular chocolate ice cream bars were recalled across 23 states. Target-branded baby food was also pulled from shelves for containing “elevated levels of lead.”

End of Article

Could This New Alzheimer’s Drug Buy Patients Four More Good Years? Here Is What We Know

Updated Aug 2, 2025 | 10:09 PM IST

SummaryA new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health. Trial results show improved cognitive scores, especially in early-stage patients, offering renewed hope in dementia treatment and early intervention.
Credits: Canva

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called lecanemab, hailed as a game-changer in the fight against dementia.

The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.

How It Works

Alzheimer’s is known for its slow but relentless grip on memory and cognition, typically marked by the build-up of sticky proteins in the brain. Lecanemab targets tau, a protein that increases as the disease worsens.

In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.

Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.

A Slow Slide Instead of a Steep Drop

Typically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.

Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.

Why Early Treatment is Key

The benefits weren’t evenly distributed. Patients who had less evidence of Alzheimer’s pathology, that is, fewer early changes in the brain, showed the most striking outcomes. In other words, the earlier you start treatment, the better your odds of preserving function.

This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.

Not a Cure, But a Clear Step Forward

Lecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.

Other Contenders in the Ring

Lecanemab isn’t the only drug showing promise. A similar treatment called donanemab was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.

That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.

The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before.

End of Article

Dizzy Spells Misread as Vertigo Led to Brain Tumour Diagnosis for 63-Year-Old

Updated Aug 2, 2025 | 08:00 PM IST

SummaryWhat seemed like simple vertigo turned out to be a rare brain tumour for a 63-year-old man. His dizzy spells were caused by a vestibular schwannoma, a benign tumour that mimics vertigo symptoms and often goes undiagnosed for months.
Credits: Canva

When 63-year-old John Starns slumped on a train station bench in Sevenoaks, drenched in sweat and struggling to stay upright, most passers-by assumed he was drunk. He looked wobbly, pale, and visibly disoriented. But what looked like an awkward case of public intoxication turned out to be something far more sinister: a brain tumour hiding behind symptoms commonly mistaken for vertigo.

From “It’s Just Vertigo” to “You Have a Brain Tumour”

Initially told he had vertigo, John tried to carry on with his life. But as the months passed, his dizziness became more intense and debilitating. At their worst, the episodes forced him to lie down, eyes shut, until the world stopped spinning. Still, no one suspected the real cause.

Three months and one MRI scan later, John finally got the truth. He reportedly had a vestibular schwannoma, a rare, benign brain tumour sitting on the nerve that connects the brain to the inner ear. It was affecting his balance, hearing, and overall coordination, symptoms that, in hindsight, were never typical of garden-variety vertigo.

What is Vestibular Schwannoma?

Despite the intimidating name, a vestibular schwannoma is not cancerous. It develops slowly over time from Schwann cells, the fatty insulation on your nerves. In this case, the tumour formed on the vestibulocochlear nerve, which governs both hearing and balance.

That is why the symptoms can masquerade as something much less serious.

  • Dizziness or vertigo
  • Hearing loss in one ear
  • Ringing or buzzing sounds (tinnitus)
  • Poor sound localisation
  • In more advanced cases, numbness on one side of the face

Because these tumours grow at a glacial pace, symptoms tend to hide for months or even years. According to Cancer Research UK, they account for around 8 per cent of all brain tumours, with risk increasing significantly after the age of 65. In rare cases, they are linked to a genetic condition called neurofibromatosis, which often causes tumours on both sides of the brain.

Why Dizziness Deserves a Second Look

Most of us treat dizziness like a mild inconvenience. You get up too fast, feel woozy for a second, then go about your day. Maybe you chalk it up to dehydration, skipping breakfast, or scrolling on your phone in bed for too long. But dizziness could be a sign of something more serious.

For John, it was not just one woozy episode. It was a string of unsettling, spin-the-room moments that left him lying flat on his back, eyes squeezed shut, praying for the world to stop pirouetting. And while vertigo was the first suspect, his brain had other plans, like growing a tumour on his vestibulocochlear nerve.

That is the thing with dizziness: it is vague, common, and often misunderstood. It can signal anything from low blood pressure and ear infections to neurological conditions that need serious medical attention. But because it is so easy to dismiss and hard to describe without wildly gesturing, it often gets brushed under the rug until it insists on being noticed.

If you face dizziness, do not ignore it. Especially if the dizziness is intense, recurrent, or comes with sidekicks like hearing loss, balance issues, or ringing in your ears.

End of Article